Using the orthotopic xenograft mouse model of breast cancer is critical for Cdc42-targeted drug development and for figuring out its pharmacokinetic properties and toxicity, which are important steps in demonstrating its efficacy. This evidence concerns the gene CDC42 and breast carcinoma.